Share this article on:

MDSC: a new player in HIV immunopathogenesis

Macatangay, Bernard J.C.a; Landay, Alan L.b; Rinaldo, Charles R.c

doi: 10.1097/QAD.0b013e328355e682
Editorial Comment

aDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

bDepartment of Immunology and Microbiology, Rush University Medical Center, Chicago, Illinois

cDepartment of Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania, USA.

Correspondence to Alan L. Landay, Rush-Presbyterian-St. Lukes Medical Cent, Chicago, IL, USA. E-mail:

Received 3 May, 2012

Accepted 14 May, 2012

Myeloid-derived suppressor cells (MDSCs) were initially described more than 2 decades ago as bone marrow suppressor cells in mice with metastatic lung tumors [1]. In the past several years, there has been increasing interest in their role in cancer immune regulation [2,3]. MDSCs are a heterogeneous group of immature and progenitor myeloid cells that undergo expansion during pathologic conditions and are characterized by their strong immunosuppressive ability [4]. This is manifested as a dampening of cytotoxic reactivity of both natural and adaptive immunity, that is, natural killer (NK) and NKT cells, and CD4+ and CD8+ T cells, respectively. Unlike MDSCs in mice which can be identified using co-expression of Gr-1 and CD11b [5], a number of different markers have been used to identify this population in humans. In some cancer studies, they have been identified as lineage negative (Lin) human leukocyte antigen DR expression negative (HLA-DR) cells that express the common myeloid marker CD33, whereas other studies defined them as CD11b+CD14+CD15+ and HLA-DR cells which express arginase-1 [6]. Recently Zhao et al.[7] described that specific members of the S100 protein family are expressed in MDSCs and that these may be useful markers in identifying this cell population. Apart from the phenotype, the mechanisms of suppression continue to be investigated. Some studies have attributed MDSC-suppressive ability to their expression of arginase-1 [8,9] and inducible nitric oxide synthetase (iNOS), whereas others point to the production of reactive oxygen species [10]. An important issue that is currently being studied is the interaction of MDSCs with other immune cells, particularly regulatory T cells (Tregs). MDSCs can induce the expansion or recruitment of Tregs, which can be an important mechanism for immune suppression [11–13].

In this issue of AIDS, Vollbrecht et al. describe for the first time, MDSCs, identified as the CD11b+CD14CD33+CD15+ cell population in HIV-1 infection [14]. The cross-sectional study showed elevated frequencies of MDSCs in HIV-1-infected antiretroviral therapy (ART)-naive patients compared to healthy controls. There was a significant positive correlation, albeit modestly, to plasma HIV-1 viremia, and a modest negative correlation with CD4+ T-cell counts. The authors report a rapid drop in MDSC frequencies upon starting ART. The authors showed that isolated MDSCs inhibited the proliferation of Gag/Nef-stimulated CD8+ T cells. Moreover, the authors report a significant increase in Treg frequencies during co-incubation experiments with MDSCs, as well as a significant positive correlation with Tregs, defined as CD4+CD25+FOXP3+ T cells.

The role of immunoregulatory cell populations in HIV-1 infection continues to be an important field of investigation. The results from Vollbrecht et al.'s study show a possible deleterious effect of MDSCs as they inhibit HIV-1-induced proliferation of CD8+ T cells. Yet, the immunosuppressive ability of MDSCs may be beneficial in curbing the damaging effects of persistent immune activation and consequent systemic inflammation associated with chronic HIV-1 infection. However, there are several important issues that should be considered in MDSC studies in HIV-1 infection. First, similar to studies on Tregs in HIV-1 infection, an important impediment is the lack of a specific marker(s) for MDSCs. Indeed, investigations of MDSCs in various cancers have used different combinations of markers [6]. Thus, contrasting results on MDSC frequency and function in HIV-1 infection could be affected by methodological differences in MDSC identification. Second, although there were significant modest correlations between peripheral MDSCs and plasma HIV-1 viremia and CD4+ T-cell counts in the studies of Vollbrecht et al., it will be important to evaluate MDSCs in tissues especially since it has been shown that the in-vivo suppression of MDSCs is limited to the inflammatory site [15]. Gut mucosal or lymph node specimens should be obtained to further evaluate the possible role MDSCs play in HIV-1 infection. Third, as in cancer studies, the specific mechanism of suppression that MDSCs use to inhibit HIV-1-specific immune responses, including their interaction with Tregs, should be investigated as this information will be helpful in designing HIV-1 immunotherapeutic strategies. In the same manner, these cells should be considered in the interpretation of immunotherapy studies. We have shown that the frequency of MDSCs, defined as LinHLA-DRCD33+ cells, is markedly elevated in HIV-1-infected patients receiving a dendritic cell-based HIV-1 vaccine [16]. The lack of efficacy of some immune-based therapies and vaccines may be due to the expansion or the increased function of immunoregulatory cells [17], including MDSCs. This finding has also been recognized in the cancer vaccine field. In a phase I prophylactic trial using mucin 1 peptide antigen and polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose adjuvant in individuals at high risk for developing colorectal cancer, nonresponsiveness to the vaccine has been linked to an increase in the frequency of MDSCs [18].

With an increasing number of HIV-1 studies focusing on HIV-1-associated persistent immune activation and HIV-1 cure, the role of immunoregulatory cell populations become more important. As with Tregs, MDSCs may be important in decreasing levels of immune activation and systemic inflammation, but at the same time, may substantially inhibit the effects of different immunotherapeutic strategies. Also, since cytotoxic T-cell responses appear important in killing reactivated cells that harbor the latent HIV-1 provirus in HIV-1 cure studies [19], dampening the effects of MDSC suppression could be vital in purging the latent HIV-1 reservoir. This possibly is noteworthy especially since histone deacetylase inhibitors, which are used to activate HIV-1 reservoirs in these studies, have been shown in murine studies to expand MDSCs [20]. As such, it is important to further define the complicated immunoregulatory network at work in HIV-1 infection. Identification of specific pathways or interactions between these immunoregulatory cells may provide the vital key to designing highly effective HIV-1 immune-based strategies.

Back to Top | Article Outline


Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline


1. Young MR, Newby M, Wepsic HT. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res 1987; 47:100–105.
2. Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 2012; 61:255–263.
3. Pak AS, Wright MA, Matthews JP, Collins SL, Petruzzelli GJ, Young MR. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 1995; 1:95–103.
4. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nature reviews. Immunology 2009; 9:162–174.
5. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172:989–999.
6. Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 2011; 11:802–807.
7. Zhao F, Hoechst B, Duffy A, Gamrekelashvili J, Fioravanti S, Manns MP, et al.S100A9 a new marker for monocytic human myeloid derived suppressor cells.Immunology 2012; 136:176–183.
8. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005; 202:931–939.
9. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65:3044–3048.
10. Rodriguez PC, Ochoa AC. T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Semin Cancer Biol 2006; 16:66–72.
11. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66:1123–1131.
12. Dilek N, Poirier N, Usal C, Martinet B, Blancho G, Vanhove B. Control of transplant tolerance and intragraft regulatory T cell localization by myeloid-derived suppressor cells and CCL5. J Immunol 2012; 188:4209–4216.
13. Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang G, Yin B, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010; 70:99–108.
14. Vollbrecht T, Stirner R, Tufman A, Roider J, Huber RM, Bogner JR, et al. Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells.AIDS 2012; 26:F31–F37.
15. Haverkamp JM, Crist SA, Elzey BD, Cimen C, Ratliff TL. In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur J Immunol 2011; 41:749–759.
16. Macatangay B, Riddler SA, Roper J, Borowski L, Whiteside TL, Rinaldo CR. Levels of cellular immune activation and myeloid-derived suppressor cells are elevated after administration of an HIV-dendritic cell therapeutic vaccine [Abstract 386]. In: Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2011.
17. Macatangay BJ, Szajnik ME, Whiteside TL, Riddler SA, Rinaldo CR. Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART. PloS One 2010; 5:e9852.
18. Kimura T MJ, Schoen R, Finn O. Prophylactic MUC1/Poly-ICLC vaccine in individuals with the history of advanced colorectal adenoma (Abstract 5380). In: 103rd Annual Meeting of the American Association for Cancer Research. Chicago, IL; 2012.
19. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36:491–501.
20. Rosborough BR, Castellaneta A, Natarajan S, Thomson AW, Turnquist HR. Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo.J Leukocyte Biol 2012; 91:701–709.

cellular immunity; myeloid-derived suppressor cell; progressive HIV infection

© 2012 Lippincott Williams & Wilkins, Inc.